Capital Analysts LLC’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Capital Analysts LLC’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-500	Closed	-$6K	–	1069
2021 Q1	$6K	Buy	+500	New	+$6.74K	﹤0.01%	855

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Analysts LLC's SGMO Position: Q2 2021 in Review

Capital Analysts LLC sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2021, closing a stake of 500 shares — an estimated $6K sold.

Capital Analysts LLC first reported a position in SGMO in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 197 funds tracked by Wall St. Rank hold SGMO as of Q2 2021.

Capital Analysts LLC reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2021 after selling out during the quarter.
Capital Analysts LLC sold 500 SANGAMO THERAPEUTICS INC shares in Q2 2021, an estimated $6K.
Capital Analysts LLC first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 1 quarter.
Capital Analysts LLC's SANGAMO THERAPEUTICS INC position peaked at $6K in Q1 2021.
197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2021.

Based on Capital Analysts LLC's 13F filing for Q2 2021, filed 5 Aug 2021.